Recent Updates
Recently added Catalysts
GRAL Positive Sentiment

GRAIL to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Key Takeaway: GRAIL, Inc. will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. The presentation will focus on the company's mission to detect cancer early using advanced technologies. Live and replay webcasts will be available on GRAIL's investor relations website. The company aims to alleviate the global burden of cancer through innovative solutions.
Price reaction · baseline $67.19 (2026-05-22 close) · hit after-hours · 1 other GRAL headline(s) in the window, move may be shared
day 0 close · peak
+2.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • GRAIL is focused on early cancer detection, enhancing treatment outcomes.
  • The company utilizes advanced technologies like next-generation sequencing.
  • GRAIL's participation in a prominent healthcare conference highlights its industry relevance.

Full Press Release Details

MENLO PARK, Calif.,May 26, 2026/PRNewswire/ -- GRAIL, Inc. (Nasdaq:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 9 at 11:20 a.m. ET.
Live and replay webcasts may be accessed in the investor relations section of GRAIL's website atinvestors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.
About GRAILGRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.
For more information, visit grail.com.

Frequently Asked Questions

When will GRAIL present at the Goldman Sachs conference?

GRAIL will present on June 9, 2026, at 11:20 a.m. ET.

Where can I access the GRAIL conference presentation?

The presentation can be accessed via live and replay webcasts on GRAIL's investor relations website.

What is GRAIL's mission?

GRAIL's mission is to detect cancer early when it can be cured.

What technologies does GRAIL use for cancer detection?

GRAIL uses next-generation sequencing and machine learning for cancer detection.

Last updated: May 26, 2026